Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 726-729

  Oefelein, Michael G ^a   Cornum, Rhonda ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE

Author keywords

Castration; Male; Prostate; Prostatic neoplasms; Testosterone

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ALGORITHM; ARTICLE; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0033900377     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67290-4     Document Type: Article

References (15)

1. Kaisary, A. V., Tyrrell, C. J., Peeling, W. B. et al: Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma. Br J Urol, 67: 502, 1991
2. Soloway, M. S., Chodak, G., Vogelzang, N. J. et al: Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology, 37: 46, 1991
3. Volgelzang, N. J., Chodak, G. W., Soloway, M. S. et al: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology, 46: 220, 1995
4. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostatic Cancer. Summary, Evidence Report/Technology Assessment. Rockville, Maryland: Agency for Health Care Policy and Research. http://www.ahcpr.gov/clinic/prossumm.htm. Accessed November 1999
5. Sharifi R., Bruskewitz, R. C., Gittleman, M. C. et al: Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther, 18: 647, 1996
6. Wechsel, H. W., Zerbib, M., Pagano, F. et al: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate IM and 3M depot in patients with advanced prostatic cancer. Eur Urol, suppl., 30: 7, 1996
7. Debruyne, F. M., Dijkman, G. A., Lee, D. C. H. et al: A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: results of studies in prostate cancer. J Urol, 155: 1352, 1996
8. Oefelein, M. G.: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol, 160: 1685, 1998
9. Wheeler, M. J., D'Souza, A., Matadeen J. et al: Ciba Corning ACS:180 testosterone assay evaluated. Clin Chem, 42: 1445, 1996
10. Hellman, L., Brandlow, H. L., Freed, S. et al: The effects of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J Clin Endocr Metab, 45: 788, 1978
11. Oefelein, M. G.: Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology, 54: 694, 1999
12. Hall, M. C., Fritzsch, R. J., Sagalowsky, A. I. et al: Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology, 53: 898, 1999
13. Millikan, R. and Logothetis, C.: Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Huntingt), 11:180, 1997
14. Crawford, E. D., Eisenberger, M. A., McLeod, D. G. et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321: 419, 1989
15. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D. et al: Bilateral orchiectomy with or without flutamide for prostate cancer. N Engl J Med, 339: 1036, 1998